Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial.

The management of poor responders in IVF has always been a big problem. The ideal approach has yet to be formulated. In this study we aim to compare two alternative stimulation protocols. A total of 48 poor responder patients described from previous cycles were included and grouped into two: group I consisted of 24 patients in 24 cycles in which leuprolide acetate (40 microg s.c. per day) was initiated on cycle day 2 followed by exogenous gonadotrophins on cycle day 3; group II consisted of 24 patients in 24 cycles in which ovarian stimulation included gonadotrophin-releasing hormone (GnRH) antagonist (cetrorelix, 0.25 mg daily during late follicular phase) administration. While only the oestradiol concentrations on the day of HCG were lower in group II compared with group I, the clinical pregnancy and implantation rates among groups did not show any significance. The impact of these two regimens in ovarian stimulation of poor responders seem to be same and to establish these results further randomized studies with larger sample sizes are required.

[1]  W. Schoolcraft,et al.  Evaluating strategies for improving ovarian response of the poor responder undergoing assisted reproductive techniques. , 2000, Fertility and sterility.

[2]  J. Hill,et al.  Will GnRH antagonists provide new hope for patients considered 'difficult responders' to GnRH agonist protocols? , 1999, Human reproduction.

[3]  J. Segars,et al.  Microdose follicular phase gonadotropin-releasing hormone agonist (GnRH-a) compared with luteal phase GnRH-a for ovarian stimulation at in vitro fertilization. , 1999, Fertility and sterility.

[4]  D. Barlow,et al.  Poor responders to ovulation induction: is proceeding to in-vitro fertilization worthwhile? , 1999, Human reproduction.

[5]  R. Fanchin,et al.  The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg. , 1998, Human reproduction.

[6]  E. Surrey,et al.  Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization. , 1998, Fertility and sterility.

[7]  J. Stevens,et al.  Improved controlled ovarian hyperstimulation in poor responder in vitro fertilization patients with a microdose follicle-stimulating hormone flare, growth hormone protocol. , 1997, Fertility and sterility.

[8]  K. Dugan,et al.  Use of the flare-up protocol with high dose human follicle stimulating hormone and human menopausal gonadotropins for in vitro fertilization in poor responders. , 1996, Fertility and sterility.

[9]  Z. Ben-Rafael,et al.  Minidose gonadotropin-releasing hormone agonist is the treatment of choice in poor responders with high follicle-stimulating hormone levels. , 1994, Fertility and sterility.

[10]  D. Navot,et al.  Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization. , 1994, Fertility and sterility.

[11]  D. Klingmüller,et al.  Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. , 1994, Human reproduction.

[12]  R. Frydman,et al.  Spontaneous luteinizing hormone surges can be reliably prevented by the timely administration of a gonadotrophin releasing hormone antagonist (Nal-Glu) during the late follicular phase. , 1992, Human reproduction.

[13]  Z. Rosenwaks,et al.  Gonadotropin-releasing hormone agonist-induced ovarian hyperstimulation: low-dose side effects in women and monkeys. , 1991, Fertility and sterility.